Simplify Logo

Full-Time

Machine Learning Scientist

Confirmed live in the last 24 hours

NewLimit

NewLimit

11-50 employees

Medicines for healthspan extension via epigenetics

Hardware
AI & Machine Learning
Biotechnology

Compensation Overview

$145k - $200kAnnually

Mid, Senior

San Bruno, CA, USA

Category
Applied Machine Learning
Natural Language Processing (NLP)
AI & Machine Learning
Requirements
  • PhD in Machine Learning, Computer Science, Computational Biology, or related field or equivalent industry experience (2+ years)
  • Experience with machine learning applications to diverse cell biology/multi-omics datasets.
  • Demonstrated ability to enable team members with high quality code and artifacts.
  • Highly self-motivated, intellectually curious, and excited to thrive in a fast-paced, multidisciplinary, and team-oriented start-up environment.
Responsibilities
  • Work closely with genomics, sequencing, and molecular biology experts to integrate internal and external datasets to drive experiment design and predict the outcome of the next rounds of experiments.
  • Develop and apply novel machine learning capabilities to model the results of functional assays and large-scale pooled-perturbation screens using single-cell multi-omics (mRNA + ATAC, scCUT&TAG) data.
  • Serve as a technical expert, taking responsibility for the execution of sophisticated predictive modeling projects and directly influencing company-level decisions.
  • Contribute to the design, decision making, and implementation of NewLimit’s technology platform.

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This process involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. NewLimit targets the healthcare market, serving pharmaceutical companies, healthcare providers, and individuals seeking anti-aging treatments. Its goal is to create a new class of medicines that significantly increase the period of life spent in good health.

Company Stage

Series A

Total Funding

$40M

Headquarters

South San Francisco, California

Founded

2022

Growth & Insights
Headcount

6 month growth

16%

1 year growth

70%

2 year growth

70%
Simplify Jobs

Simplify's Take

What believers are saying

  • Securing $40 million in Series A funding from prominent investors provides a strong financial foundation for growth and innovation.
  • NewLimit's pioneering approach to reversing aging could lead to groundbreaking treatments for age-related diseases, offering significant societal impact.
  • Partnerships with pharmaceutical companies and healthcare providers could accelerate the commercialization and adoption of their anti-aging medicines.

What critics are saying

  • The field of epigenetic reprogramming is still in its infancy, posing scientific and regulatory challenges that could delay product development.
  • High reliance on advanced technologies like machine learning and single-cell genomics may lead to operational complexities and increased costs.

What makes NewLimit unique

  • NewLimit focuses on epigenetic reprogramming to extend healthspan, a niche yet revolutionary approach in the biotech industry.
  • The integration of single-cell genomics, machine learning, and high-throughput functional assays sets NewLimit apart from traditional biotech firms.
  • Co-founded by high-profile individuals like Coinbase CEO Brian Armstrong, NewLimit benefits from strong financial backing and industry connections.